Trans Retinoic Acid (Vesanoid) With Chemotherapy in Non-Small Cell Lung Cancer
- Determine the response rate and duration of response to mitomycin, vinorelbine, and
cisplatin plus tretinoin in patients with stage IIIB or IV non-small cell lung cancer.
- Determine the toxicity of this treatment regimen in these patients.
- Determine survival of these patients with this treatment regimen.
OUTLINE: Patients receive tretinoin orally twice daily for 4 days starting days 1 and 8;
cisplatin IV over 2 hours and vinorelbine IV on days 1 and 8; and mitomycin IV (courses 1
and 3) on day 1. Treatment repeats every 3 weeks in the absence of disease progression or
Patients are followed for survival.
PROJECTED ACCRUAL: At total of 15-46 patients will be accrued for this study.
Primary Purpose: Treatment
Raghu Nandan, MD
Raghu Nandan, M.D., Inc
United States: Federal Government
|Rajendra Prasad M.D., Inc.||Lakewood, California 90712|